

**MANAGEMENT'S DISCUSSION AND ANALYSIS
OF THE COMPANY'S FINANCIAL CONDITION AND RESULTS OF OPERATIONS
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2018**

FORM 51-102F1

Date and Subject of Report

The following Management Discussion & Analysis ("MD&A") is intended to assist in the understanding of the trends and significant changes in the financial condition and results of operations of Certive Solutions Inc., and/or Certive Health Inc. (formerly Certive Technologies Arizona Inc.) ("Certive" or the "Company") for the nine months ended February 28, 2018. The MD&A should be read in conjunction with the audited annual financial statements of the Company as at May 31, 2017. The MD&A has been prepared effective April 30, 2018.

SCOPE OF ANALYSIS

The following is a discussion and analysis of the Company, which was incorporated on June 11, 2010, under the laws of the Province of British Columbia. The Company's head office is located at 1140-1185 West Georgia Street, Vancouver, B.C., V6E 4E6. The Company reports its financial results in U.S. dollars and under International Financial Reporting Standards.

Overview

During the nine months ended February 28, 2018 and the subsequent period up to and including the date of this MD&A, there were no significant or material events that occurred other than as reported herein. All amounts expressed herein are in U.S. dollars.

On April 5, 2018 the Company announced that the Board of Directors had approved in principle conducting a Plan of Arrangement that would among other matters, subject to regulatory approval, result in Certive transitioning to an Investment Company. In connection with the Plan of Arrangement the Company will spin out several corporations that will become reporting issuers in Canada and may seek to list their shares on the Canadian Securities Exchange (the "Exchange").

One of the spin out companies will acquire the Company's current wholly-owned subsidiary Certive Health Inc. ("CH"), enabling Certive Health Inc. to attract additional capital within the United States.

The primary objectives in conducting the Plan of Arrangement are summarized as follows;

- a) To divest via spinout, CH, a wholly-owned subsidiary.
- b) To settle all convertible debt currently in the Company.
- c) To increase shareholder value by providing to the Company's shareholders, shares in four proposed spinoffs with each spinoff completing its own financing including that of CH.

d) To re-qualify the Company as an investment issuer with \$2 million in funding.

All shareholders of the Company, will upon completion of the Plan of Arrangement, retain their original ownership in the Company, and have mirror image ownership in all of the spin out companies at no additional cost to the shareholders.

The Plan of Arrangement process remains in a preliminary status at the date of this MD&A.

As reported in the MD&A for the quarter ended November 30, 2018 (CH) continues to operate below breakeven sales and cashflow levels, however with the prospects that have been identified in the past three months, management believes that CH may reach breakeven sales volumes before the Company's fiscal year end, May 31, 2018. It is also projected that over the following three months, CH will require a minimum of \$500,000 in capital to cover operating costs.

Also, during this reporting period, up to and including April 30, 2018, CH, with the approval of the Company's Board, appointed several new members to the CH board in an attempt to provide direction and support in the management of CH. Tom Marreel was appointed Chairman of the Board of CH and Jack Saltich, a former director of the Company was appointed a director along with Tim Hyland. Michael Miller assumed the role of CFO of CH.

In the course of completing the Plan of Arrangement, it is the Company's intention to enable CH to become an independent reporting issuer in Canada and complete the requirements to list on the Exchange. This process will be conducted concurrently with the broader intricacies of the Plan of Arrangement and the transition of Certive Solutions Inc. to an investment company.

These changes were made with the full support of CH's only shareholder, the Company and the Board of the Company. During the transition however, the Company will continue to monitor CH until the spinout is concluded.

Mike Bartlett continues in the role of CEO and Chairman of the Board of the Company and Brian Cameron continues in the role of CFO of the Company. On March 6, 2018, Scott Thomas was appointed to the Board of the Company. Van Potter remains the CEO of CH.

As noted elsewhere in this MD&A, CH has engaged with a seasoned healthcare sales and marketing professional to develop and execute a plan to achieve positive operating cash flows that could reduce or eliminate the continuing need for the Company to fund its operating subsidiary.

The Company is in the process of implementing several re-organizational plans that will align CH's operating costs to customer demand. Included in these plans is an immediate cost reduction which will reduce the payroll burden on current operations while enabling CH to support existing customers and have the capacity to bring new customers on stream as contracts are obtained. If and when, several anticipated new customers are secured and begin to generate sales the burden of seeking outside capital to support operations will terminate.

As noted in the MD&A for the quarter ended November 30, 2017, CH must become independently viable and remains not so as of the date of this MD&A. Accordingly readers should rely upon the going concern qualification in the recently completed audited financial statements dated May 31, 2017.

Summary of Current Corporate and Financial Status

Effective June 1, 2017, the Company sold its Titan Division as noted elsewhere in this MD&A. The effect of the sale is that comparative revenues for the nine months ended November 30, 2017, as compared to the reported revenues for the nine months ended November 30, 2016 are materially lower.

With the sale effective June 1, 2017, the Company has utilized the 1st, 2nd and 3rd quarters of fiscal 2018 to accomplish several milestones which are not reflected in the financial performance of the Company at the date of this MD&A. These initiatives are associated with a complete re-branding of the business including, updating the Company's web presence, identifying target customers that can be reasonably closed within the following six months, specific cost containment measures both at the operational level and corporately to conserve cash for sales and marketing activities and an investiture in human capital and current technologies to ensure the relevancy of our services to customers.

Onboarding a new Chief Growth Officer was and remains a key to the strategies that CH will deploy. . The Chief Growth Officer is a seasoned healthcare professional with years of experience in the development and implementation of sales and marketing strategies for his own enterprises and those of large enterprises in US healthcare.

Material Events That Occurred During the Quarter Ended February 28, 2018

1. On January 22, 2018, the Board of Directors of the Company agreed to accept \$240,000 and 160,000 post consolidated shares of AXS Blockchain Solutions Inc. (formerly Canadian Data Preserve Inc.) (from third party investors) in full satisfaction of an amount owing to the Company by Canadian Data Preserve Inc. The receivable had previously been written off by the Company, due to the fact that it was deemed uncollectable. The \$240,000 has been paid and the 160,000 post consolidated shares will be issued to the Company shortly.

Material Events That Occurred Subsequent to the Quarter Ended February 28, 2018

1. The Company announced its intention to conduct a Plan of Arrangement and re-organize its affairs as noted above.
2. The Company appointed Scott Thomas to the Board of Directors, effective March 6, 2018.

Summary of Corporate Status as at February 28, 2018

Commencing, June 1, 2017, the Company's operating divisions are Omega Technology Solutions Inc. ("Omega") and Knowledge Capital Alliance Inc. ("KCA") Omega and KCA are wholly owned subsidiaries of the Company.

Omega's positioning in the revenue cycle market and management's strategic plan for growing Omega and the anticipated results of the strategic plan are discussed elsewhere in this MD&A.

As of the date of this MD&A, the Company's consolidated financial status is summarized as follows:

- Results of Operations for the nine months ended February 28, 2018 are summarized as follows:

	<u>Omega</u>	<u>KCA</u>	<u>Certive</u>	<u>Total</u>
Revenues	\$948,856	\$289,749	\$0	\$1,238,605
Operating Costs	<u>796,682</u>	<u>272,152</u>	<u>\$0</u>	<u>1,068,834</u>
Gross Margin	152,174	17,597	\$0	169,771
Expenses	<u>696,261</u>	<u>55,456</u>	<u>1,769,031</u>	<u>2,520,748</u>
Net Income (Loss)	(544,087)	(37,849)	(1,769,031)	(2,350,977)

With the divestiture of the Titan division, all capital resources allocated to CH will be directed towards;

- a) Sales activities throughout the United States where the Company has C level access to administrators, supported by our new relationship with connectors such as Midwest Insurance Consultants LLC and;
- b) Support the infrastructure necessary to enable growth.

Certive Solutions Inc -Plan of Arrangement Process Overview

To date, the Company has spent over USD\$7,000,000 on CH and its subsidiaries, largely to finance the operations of both Titan Health Management Solutions Inc. (Titan), which was sold back to the founders in the fall of 2017, and Omega. The expenditure is reflected as an intercompany advance from the Company to CH and is secured by promissory notes. As its Chief Growth Officer Tim Tolchin, has proven to be a valuable asset, as many new product category opportunities have been identified that originate from utilizing proprietary technologies created and refined over many years at Omega. These offerings are proving to have near-term results that will become more evident in the following reporting periods.

CH is now poised to take advantage of its technology and connectivity in the revenue cycle process, leveraging the relationships and creative thinking of its Chief Growth Officer.

In the course of achieving the many goals CH has set for itself over the following 24 months, management and the Board of the Company has determined that a fundamental re-structuring of

the operating subsidiary is necessary in order to appropriately finance its anticipated growth, while providing all of the Company's investors with multiple opportunities. Management has concluded that by conducting a plan of arrangement (POA), a vehicle by which multiple new corporations are "spun out" out of the Company, it can reorganize its business to enable more appropriate financing of CH at minimal investment by the Company's current shareholders and no investment in the spinout.

In the process, the Company intends to apply to transition to an investment company pursuant to CSE policies and requalify to list on the CSE as an investment company.

Plan of Arrangement Process – Generally

A plan of arrangement is a statutory procedure available under the *Canada Business Corporations Act* (CBCA), as well as under provincial corporate statutes. Where a corporation wishes to combine (or to make any other "fundamental change") but cannot achieve the results it wants under another section of the statute, it can apply to the court for an order approving a proposed "plan of arrangement". In the right circumstances, a plan of arrangement can be a substitute for the other common acquisition mechanisms, such as the statutory amalgamation and the take-over bid.

The plan of arrangement's flexibility in complex business combinations and restructurings can be highly attractive. In the M&A context, arrangements often allow what would otherwise be multi-step transactions to be completed in one stroke.

To effect an arrangement, the parties would enter into a definitive arrangement agreement, essentially a "merger" agreement, setting out the principal terms of the transaction, together with the parties' representations, warranties, and covenants, as well as any conditions precedent to the obligations being assumed.

The Court Process

Upon entering into the arrangement agreement, the parties would apply to a court for an "interim order" that will give directions on calling and giving notice of the meeting of securityholders, the conduct of the meeting, and the level of approval by which securityholders of each class must approve the arrangement (usually 66 $\frac{2}{3}$ %). In practice, the court will almost always grant rights of dissent to securityholders, which when exercised generally entitle the dissenter to be bought out at "fair value".

On obtaining the interim order, the target will be required to prepare and distribute a management proxy circular prior to the meeting. Assuming that approval is obtained, the plan of arrangement is then submitted for final court approval. This is usually granted if, in the view of the court, the plan is "fair and reasonable".

The flexibility of the arrangement process is suggested by s. 192(4) of the CBCA, which states that, in response to such an application, "the court may make any interim or final order it thinks fit". As a result, any necessary fundamental changes can potentially be effected in the course of an arrangement, including amendments to articles, amalgamations, share-for-share exchanges, and transfers of assets. A plan of arrangement allows two merging corporations to deal not only with

their respective shareholders but also with other securityholders and, to varying degrees, even with creditors. Plans of arrangement are therefore particularly useful where the target has a complex capital structure with many stakeholder classes, some or all of whom must be compromised or otherwise have their rights modified, or where a reorganization of the assets, capital or corporate structure of one or more of the merging corporations would allow the merger or acquisition to proceed on a more tax-effective basis.

It is also worth noting that, in Canada-U.S. cross-border transactions, plans of arrangement are usually the simplest way to create an “exchangeable share” structure – involving the issuance of “mirror shares” designed to be the equivalent, functionally and economically, to the acquirer’s common stock in all material respects – which allows Canadian shareholders to receive tax “rollover” treatment. Rollovers are not normally permitted under Canadian tax law where shares of a foreign acquirer are exchanged for those of a Canadian target.

Further advantages of the plan of arrangement structure are that it:

- facilitates compromise among different stakeholders because its flexibility allows different groups within the same class of securities to be offered different consideration under the transaction;
- permits the acquirer to cause the target to effect structural changes, prior to closing, that have a tax benefit to the acquirer, but which the target might otherwise be reluctant to carry out before closing (such changes can be carried out after securityholder and court approvals have been obtained and before closing); and
- can make it difficult for disgruntled securityholders to attack the merger once the court has determined the “fairness” of the transaction.

Certive Solutions Inc. Plan of Arrangement Process Summarized

The Company will, as an integral part of the POA, undertake certain steps to re-structure itself in order to undertake a proposed spinout of 4 new wholly owned subsidiaries, each of which will receive assets from the Company in exchange for issuing shares to the shareholders of the Company.

CH is currently a wholly owned subsidiary of the Company and it proposes to requalify as an investment company pursuant to the policies of the CSE, and may select CH as a potential investment target, holding up to a maximum of 20% of CH.

CH Spin Out.

As part of the POA, the Company intends to create one (1) spinoff that will inherit the existing CH assets at the outset. The spinoff will select a new name that can be marketed to the U.S. healthcare sector. It is proposed that the Company will retain an equity interest in CH and that some portion of its investment in CH will be treated as a long term note due to the Company.

FORWARD LOOKING STATEMENTS

The information set forth in this MD&A contains statements concerning future results, future performance, intentions, objectives, plans and expectations that are, or may be deemed to be, forward-looking statements. These statements concerning possible or assumed future results of operations of the Company are preceded by, followed by or include the words ‘believes,’ ‘expects,’ ‘anticipates,’ ‘estimates,’ ‘intends,’ ‘plans,’ ‘forecasts,’ or similar expressions. Forward-looking statements are not guarantees of future performance. These forward-looking statements are based on current expectations that involve numerous risks and uncertainties, including, but not limited to, those identified in the Risks Factors section. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are reasonable, but any of which could prove to be inaccurate. These factors should be considered carefully, and readers should not place undue reliance on forward-looking statements.

In this MD&A, the Company has specifically noted the forward-looking nature of comments where applicable. Generally, readers should be aware that forward-looking statements included or incorporated by reference in this document are related to its operating subsidiary CH and, that it is the Board’s intention to divest itself of CH by way of the Plan of Arrangement. As the Company seeks approval to transition to an investment company, and identifies appropriate investments, these forward looking comments will become less relevant to its business. All of the disclosures in the balance of this MD&A relate to the historical business of the Company which may change as the Plan of Arrangement process completes.

At the date of this MD&A however these comments on forward looking matters are relevant and should be considered by readers. They include the following.

Factors impacting the growth of CH:

- a) The CH’s near term organic growth strategy is based upon the scalability of Omega operationally and the ability to access key decision makers such as CFO’s and revenue cycle executives in targeted hospitals. The connector process is a primary sales tool for the Company.
- b) The identification of selected acquisition targets that complement the core business is a key factor that will impact growth. The Company and CH have identified targeted opportunities in the analytics sector of U.S. healthcare that both complement current service offerings or provide the potential create new offerings by combining intrinsic resources.
- c) The identification of new lines of business within revenue cycle management for U.S. hospitals that are unique and provide value added benefit for hospital administrators.
- d) The ability to cross-sell different services between and among the CH’s customers resulting from selected acquisitions.
- e) Expectations of both divisional profitability and comprehensive corporate profitability for the consolidated enterprise.
- f) Expectations regarding the ability to raise capital to fund increasing working capital requirements and achieve sustainable near and long-term growth. Partially cash funded

acquisitions may lead to substantial dilution if the majority of the acquisitions are stock based.

- g) The CH must be mindful of a downward move by upper market tier participants who recognize the opportunities in the tier 3 highly fragmented market space.
- h) The CH must assess the relative risk associated with acquisition size, category of revenue integrity services provided and the need for working capital to support the growth of each acquisition.
- i) The CH must be mindful and reactive to disruption in the U.S. healthcare markets and target, both acquisition opportunities and internal growth with a focus on this disruption to achieve maximum rates of return on internal cash.
- j) As the CH expands its service offerings, it will need to ensure that there is a constant vigilance over new and changing regulations that will impact the ability to remain compliant.
- k) The Company will continue to direct and manage the affairs of CH and its Board until the divesture and transition is completed.

General History

The following is a chronological description of the Company's history and the basis for its entrance into the revenue cycle management ("RCM") sector of the U.S. healthcare industry:

- The Company changed its name to Certive Solutions Inc. in October 2013 to pursue sales and marketing opportunities as a business process management provider focused on revenue lifecycle management in the U.S. healthcare industry. The Company's Chairman at that time, Mr. Shackleton, was instrumental in bringing mission critical expertise to the Company. Mr. Shackleton resigned from the Board for personal reasons during the year.
- In late 2013 and largely due to a market assessment performed by management in the fall of 2013, the Company narrowed its strategic focus to the provider side of the U.S. healthcare industry and specifically to U.S. hospitals, who wrote off between 3% and 15% of their total revenues to denied claims for a variety of reasons.
- In March 2014, the Company entered in to a strategic relationship with Titan, a company with over twelve years of domain expertise supplying revenue cycle management services on an outsourced basis to U.S. hospitals. The Company's technology and capital formation expertise combined with Titan's knowledge of the many opportunities in revenue cycle management, led to a logical partnership. Ultimately this led to the Company's acquisition of the Titan assets in July 2014 and the integration of Titan's management team and staff into the Company's operations. During the last fiscal quarter, , the Company and the Titan principals concluded that the goal objectives associated with the zero balance business, operated by the Titan principals was incongruent with the long term strategic plan for the Company and accordingly the agreement for the Titan principals to repurchase the assets acquired by the Company was determined to be the most equitable way to minimize the

Company's expected future capital commitment to the division and yet not minimize the opportunity for the Titan principals. (See other sections of this MD&A for additional disclosure).

- The acquisition of the assets of Knowledge Capital Alliance Inc. (KCA) closed on August 31, 2014. Certive recently completed the acquisition of 100 percent of the equity in Knowledge Capital Alliance ("KCA") effective March 13, 2017. This transaction was a restructuring of the asset acquisition of KCA referred to above. It was determined that the acquisition of the equity of KCA will be complementary to the organizational structure of Certive and the KCA brand. The equity of KCA was purchased in consideration for a total of 1,350,000 common shares of Certive at a deemed value of US\$0.30 per share. Certive's guarantee of an outstanding note to a KCA shareholder in the amount of US\$256,000 was also forgiven. KCA provides business process management solutions to public health departments at both the state and county level. KCA has developed an automated dashboard tool set and workflow technology that will be offered to over 2800 public health organizations throughout the United States. Moreover, the principals of KCA supports the Company's consultative efforts as it seeks out new lines of business within revenue cycle management of U.S. hospitals. During the past two years, KCA has steadily enhanced its delivery of process management solutions to state and county governments, particularly specializing in business process management for public health-related matters through the implementation of cloud-based applications. This has significantly improved KCA's product offerings to agencies throughout the United States.

During the past year, KCA has been focused on selling its VMSG Dashboard branded performance management system to public health departments in the United States. The VMSG Dashboard is a performance management system designed specifically to assist public health departments in the development, implementation and performance management of the Strategic and Operational Planning process. The Dashboard facilitates quick and accurate planning changes and is designed to allow both internal and external users to keep their plans up-to-date in real time. For public health departments seeking PHAB accreditation, the VMSG Dashboard has been designated as "fully demonstrated" by the Public Health Accreditation Board for Standard 9.1 applicable to most U.S. public health departments. KCA's customer base has grown from 27 health departments in 10 states to 55 health departments in 17 states in just over 10 months, and the opportunity pipeline has grown significantly from 45 to over 160 public health departments with an expected 300% increase in potential annual revenues. The VMSG Dashboard is a software as a service (SaaS) recurring revenue business model. As new public health units license the VMSG Dashboard, the recurring revenue grows. An additional benefit as SaaS provider is KCA can continuously upgrade its service to all clients, responding quickly to the client's changing needs. The U.S. healthcare market is changing as reform initiatives drive to lower costs, improve outcomes, and improve the general health of the population. U.S. public healthcare departments will work more closely with local care providers which Certive believes will provide opportunities for expanded services for both Certive and KCA. As KCA expands its presence throughout the nation, it is also expanding its presence at major annual conferences such as the National Association of City and County Health Officials

which is attended by over 1,300 public health leaders. Recently the Company was invited to present to 44 health departments at TACCHO conference in Austin, Texas.

- On July 15, 2015, the Company acquired the assets of Omega Technology Solutions LLC (Omega). With the acquisition of Omega, the Company has a technology base and the ability to provide charge capture services on a retrospective and prospective basis. There are a total of 1,500 targeted hospital in the U.S. that have applicability to the service offering. Each target has been assessed based upon Omega's proven assessment analytics using commercially available and reported data on the hospital targets on AHD. Omega has made a significant investment in revenue integrity analytics technology that is the foundation for its delivery of revenue services and cloud products that identify revenue opportunities and address compliance issues. Omega's solutions deliver real-time analysis and capture of unidentified charges not captured by the hospital, and prevention of charging and billing issues that reduce or delay reimbursement. Additional services offered include comprehensive claims analysis for coding integrity, and revenue leakage prevention. Omega collects zero balance claims from the hospital system up to 2 years. Those claims are compared to the patients' medical record by our RN auditors. The auditor then looks for missing charges, coding or compliance errors. Omega's in-house billing department then directly bills the insurance company based on the findings (unless the hospital system prefers to do their own billing). The hospital system receives payment directly on the billed charges. Omega performs follow-up and dispute resolution for claims submitted. In addition to finding revenue, Omega routinely educates the hospital and its staff on its findings. Omega provides detailed monthly reports of its findings in conjunction with periodic meetings to discuss specific patterns and problems, establishing a process to prevent losses from occurring in the future. Omega goes back two years with its clients in the auditing process, and prepares them for their future through preventative training and education. The Lost Charge Recovery system has no upfront cost, no risk and only an upside potential for the hospital.

General Comments on the Company and its Current Business in Revenue Cycle Management for U.S. Hospitals

REVENUE CYCLE MANAGEMENT FOR HOSPITALS – A DEFINITION

All healthcare providers depend on three types of payment sources: self-pay by the patients, insurance company benefit payments and government-based programs (principally Medicare and Medicaid). The process of billing and collecting such payments has grown more complex over the years as insurance and governmental programs have become more intricate. Uninsured and the higher deductible insurance policies have forced a greater need to collect payments directly from patients. Many hospitals lack the technical sophistication to adequately bill and collect from these various payment sources.

Revenue Cycle Management ("RCM") systems have developed over the past twenty years to address these needs of hospitals and other healthcare providers. The RCM process is composed of the following segments:

- Scheduling and Eligibility
- Pre-Registration and Financial Clearing
- Admitting, Registration
- Point of Service Charge Capture
- Case Management
- Coding
- Pre-billing and Billing
- Submission to Payers – Patient and Third-Party Payers
- Payment Posting
- Denial and Payment Analysis
- Self-Pay and Collections

The Company provides revenue cycle services to U.S. hospitals. Certive identifies categories of opportunity within the traditional revenue cycle for hospitals and on an outsourced basis provides effective recovery of revenue on claims that are retrospectively assessed as underpaid or missed in the billing process. The goal is to optimize reimbursement, increase operational efficiency, and minimize the cost of compliance risk for Certive’s customer.

Certive Solutions Inc. currently operates its wholly owned subsidiary Certive Technologies Arizona Inc. (“Certive Health”), an Arizona corporation, located in Scottsdale, Arizona. Under Certive Health there are two operating units, Knowledge Capital Alliance Inc. (“KCA”), and Omega Technologies Solutions Inc. (“Omega”).

CERTIVE ARIZONA’S RCM PLATFORM

Certive Arizona has developed a business plan to provide a comprehensive platform to deliver individual and coordinated services for the segments of RCM following the delivery of healthcare services: Coding through the Self-Pay / Collections segments. At present, Omega provides service offerings in the following areas:

Charge Accuracy Audits

This includes audit of patient charts against the medical record to capture charges for services that were performed but not billed to payers. Fees are based on a percent of the lost charges that are recovered.

Claim Audit and Recovery services.

This includes the retrospective review of payments made from payers based on the contracts – this identifies underpayments based on improper billings by the hospital, improper contract interpretation by the payers and appeals of claim denials. Fees are usually based on a percentage of additional revenues paid to the hospital as a result of the audits and appeals.

Identifying new opportunities not easily identified by other participants in revenue cycle is a distinguishing characteristic of Certive which remains the key undertaking of the Company.

Leveraging trusted relationships that have matured over many years with all Certive's customers, is a key component of the long-term strategy. Defining a positive future for the challenges facing U.S. healthcare and, in particular revenue recognition, will be predicated not only upon services to providers and payers alike, but also defining the new information landscapes that will emerge and providing technology toolsets that enable managers of large hospital systems to better predict financial outcomes for services rendered. Certive continues to approach its customers with this unique culture and identity.

CH intends to selectively grow its access to new customers through acquisition of companies that provide services to hospitals that are much needed and relate to the increasing urgency to identify better overall outcomes on reimbursement. The footprint alone is merely a starting point. With a growing customer base, the Company can sell more services to its customer base and cross sell offerings between and among those customers and develop analytical tools to mitigate three primary risks associated with any provider business:

- Eligibility/Enrollment Risk
- Patient Services Risk
- Collection Risk

The opportunity is to use the Company's analytical capabilities to identify missing information links in the revenue cycle, disrupted by ICD 10, and to create new service and product offering uniquely tailored to the changes impacting healthcare delivery and payment.

Certive has an Advisory Council, with members that cumulatively have credentials which are unrivaled in the U.S. healthcare market. Each Advisory Council member will be given a special project associated with Certive's strategic and tactical plans, together with time lines for completion. It is anticipated the upon conclusion of the Plan of Arrangement, that this Advisory Council will transition to CH.

The purpose of the Advisory Council is to provide direction, guidance and special project based support to management in the design and implementation of business strategies aimed at creating overall near and long-term enterprise value. The Advisory Council was formed specifically to assist management and the Board of Directors in determining the best strategies to effect growth in an ever-changing U.S. healthcare market. Current members of Certive's Advisory Council are:

- Dr. Arthur Pelberg, an internal medicine specialist, served as the President and Chief Medical Officer of Schaller Anderson from 1999 to 2007 and brings to the Company rich clinical and senior level healthcare operations experience.
- Fred Hatfield, formerly CEO and COO of Aetna Medicaid and head of acquisition integration for Schaller Anderson.
- Tim Hyland, former CFO of Schaller Anderson.
- Tom Marreel, formerly senior vice president of Schaller Anderson.
- Steve Schramm, the founder of Optumas, an actuarial analysis organization for large healthcare purchasers. Mr. Schramm's background brings to Certive the knowledge to use

sophisticated actuarial and analytics toolsets that derive meaningful provide its customers with meaningful information health data.

- Jeffrey Benton is currently the managing director of Fairfield Advisors, a hedge fund specializing in market structure arbitrage and volatility strategies. Mr. Benton brings to the Advisory Council years of experience in the translation of business operating strategies to investment information and tools that will, in Certive's case, serve to better enable effective investor relations communications. Mr. Benton is a distinguished and highly regarded member of the U.S. investment community, having served on a number of New York Stock Exchange committees over the years. Mr. Benton is a former Governor of the New York Stock Exchange.
- Don Gilbert has extensive background in healthcare, particularly in the State of Texas where he served as Secretary of Health and Human Services under Governor George W. Bush.
- Michael Marshall, CEO of e5 Workflow Inc. joined the Advisory Council in December 2015 and provides to Certive, operational capabilities in revenue cycle management with hands on expertise in all aspects of this industry.
- Bob Uxa - Bob Uxa is an accomplished professional with over 35 years of experience, internationally, in the aluminum industry where he developed and implemented new strategic plans for commodity marketing, procurement and risk management for one of the world's largest brewers and recyclers. Mr. Uxa pioneered commodity sourcing from Russia, India, the Middle East and South America for U.S. Manufacturers and was at the leading edge of product line expansion for the aluminum industry.
- William Dagher is a healthcare professional and revenue cycle expert.

The Company's mission is to demonstrate through execution, operational excellence in identifying, billing and collecting missed charges through an audit and collection process that blends unique technologies and workflow tools together, thus providing usable billing related information and enhancing integrated collection results for customers.

Members of the Advisory Council have all invested in Certive and are committed to assisting in charting its course through growth by acquisition and organically.

The Company's Business

The Company is a Scottsdale based, British Columbia domiciled, reporting issuer, publicly traded on the Canadian Securities Exchange (CSE: CBP). Effective September 16, 2014 the Company's shares began trading on the Frankfurt Exchange (FWB: 5CE) and on July 15, 2015, the Company's shares were quoted on the OTCQB Capital Markets in the United States under the trading symbol "CTVEF". The Company has two wholly owned subsidiaries; Advantive Information Management and Certive Technologies Arizona Inc., each operating as independent subsidiaries.

Description of the Business

Executive Summary - The Business

Certive through CH, principally provides charge accuracy services that support revenue cycle management in the central business offices of U.S. hospitals by targeting revenue categories where reimbursement recoveries can be secured through a combination of highly skilled clinical staff and proven workflow tools.

During the fiscal year ended May 31, 2017, the Company engaged in both the recovery of denied claims and the recovery of amounts that were never billed to the insurance company (Lost Charge Recovery). Up to that date, the majority of all denied claims recovery was undertaken by the Titan Division, although the Omega Division regularly provided these services but they did not brand themselves directly as a Denial Management enterprise. With the departure of Titan, the Company will continue to offer these services but as an integral part of the Omega category of business.

The U.S. healthcare market is highly disruptive and currently accounts for in excess of 30% of the U.S. GNP. Current challenges to the Affordable Care Act, specifically reform, and changing reimbursement models add fuel to this disruption. As provider solvency issues grow, increased government scrutiny will force new costs upon an already choking system. As increased copays and deductibles put more responsibility on the patient, the self-pay component of provider revenue continues to rise making providers concerned for their future. C-level hospital and physician group executives not only need better business process management tools to equip them for survival, but more importantly, a focused new solution for this specific need. The need for relevant information that defines operating risks is becoming increasingly more important. Access to information immediately prior to the delivery of service, derived from already existing data that quantifies patient financial risk, patient service risk and patient collection risk, will become the holy grail, as this disruption determines who will survive.

The delivery of healthcare is becoming consumer-centric. Certive's goal is to be strategic in its acquisition plans and organic growth-based business model to enable Certive to take advantage of this change. If Certive can improve the financial performance of its U.S. hospital clients, Certive will be a leader in this industry. By targeting accretive acquisitions that expand Certive's customer reach with services that are needed for success and leverage its presence for organic growth, the Company will rise above its competitors. Using analytics and Certive's vast database of historical data, the Company will create unique relevant operating models for its customers to that address the fundamental risks associated with running any hospital. With that, the value of Certive will grow.

Certive, through CH, specializes in recovering cash for hospitals by auditing patient charts and comparing them to the medical records to discover items and services performed but never billed to the insurance carriers. Certive's has over 20 years of experience providing these services and with that, access to vast quantities of retrospective data from which to develop the analytical tools necessary to effectively manage risk.

Certive Health Inc. (formerly Certive Technologies Arizona Inc.) a wholly owned subsidiary of Certive Solutions Inc. (CH)

CH is an integrated health care consulting and revenue cycle management company focused on providing revenue cycle management services and tools to U.S. health care providers and payers, with the core objective of minimizing the financial risks associated with the delivery of health care all within a disruptive and ever- changing environment.

CH owns and operates a charge accuracy and chart review business located in Ft. Lauderdale, Florida, known as Omega Technologies Solutions Inc. Utilizing proprietary software and skilled nurse auditors, Omega audits hospital bills that have been previously scrubbed by standard software programs, compares the audit findings to the original bill sent to the payer, and identifies lost charges retrospectively over a two-year historical period. Omega has over 20 years experience conducting these audits and has developed standard protocols with predetermine the extent to which any hospital facility may have pools of lost charges that were never billed to the payer.

CH intends to expand its presence in revenue cycle management by acquiring additional and complementary enterprises focused on the identification, quantification and management of financial risks associated with the delivery of health care services and improving the efficiency of that delivery

CH intends to expand its presence in the revenue cycle management segment by incrementally developing five additional and complementary solutions and bundle them into a single platform for efficiency and accuracy. New lines of business focused on the financial risks and outcome risks of health care not only for today's fee-for-service model, but will accelerate and enable key aspects of healthcare reform. These lines of business will be built using of a combination of current capabilities, development of sophisticated new analytical models on top of our current capabilities, and strategic acquisitions. These solutions will not only capture the leakage in the system but will provide defined process improvements in several niche areas to solve the root cause of the problem. The program will be led by one of Certive's Advisory Council members who has over 28 years' experience in healthcare and is founder and owner of a well-known healthcare analytics and actuarial services company and is focused on healthcare reform for State Medicaid programs. His firm holds the position as the second largest actuary of record to individual States in the U.S.

As part of the plan, CH has defined and will implement a best in class a digital web presence to attract investors, clients, and potential acquisition or partner candidates. This digital marketing program is designed to communicate more about the company and its core vision to attract people who bring accretive talent, ideas, or their companies for Certive to evaluate for potential acquisition.

CHs Differentiator



The Company has assembled an outstanding Advisory Council consisting of over 15 experienced senior healthcare executives who have built, lead, and sold significant enterprises in the healthcare market, and possess broad complimentary skills. The Advisory Council, their network of executive leads, subject matter experts, and the extended network of experienced healthcare talent at the “doer” level is Certive Tech’s differentiator.

Competitive Landscape:

There are three categories of competitors: a) In-sourcing by Certive’s target hospital clientele; b) indirect competitors that offer technology solutions, and c) direct competitors that offer services.

- a. Hospital In-Sourcing: This is the status quo. Hospitals do not have the internal resources and efficiencies to do this alone and have long relied on vendor relationships to help manage through the complex reimbursement and revenue cycle process and this will not change. Increasing complexities, reduced reimbursement, focus on outcomes, rising costs of care, consolidation, and changes in the regulatory environment have resulted in increased financial pressure on the hospitals and the need for improved efficiency. All this results in an increased market opportunity for vendors who can deliver.
- b. Indirect Technology Vendors:
 - i. Several vendors such as MedAssets, Craneware, etc. provide technology solutions that attempt to solve the hospitals problems. Hospitals, however, are resistant to further reinvestment in more “systems” and need to have their problems solved, when in fact, these solutions actually contribute to the problem by often reducing claim value allowing greater leakage to occur. Often, hospitals are frustrated with pure technology solutions as, in the absence of a strong service component, they fail to deliver on the promised value proposition.

- ii. Large health information management (HIM) providers such as Cerner and Epic are technology suppliers to the industry that are seeking to add a viable service component to their revenue models. In the absence of acquisition strategies, they are unlikely to move fast enough to catch the changing landscape in the services model. They do however possess unique access to new customers and every implementation of the systems raises a large revenue leaking issue for the hospital that must be addressed. Certive on the other hand, is a service company with net free cash flow that can quickly adapt to change and identify risk management solutions that become useful “extenders” to the current services offering of these providers. Certive then becomes a very important piece of the puzzle to these competitors who are ill equipped to move quickly. Certive, therefore, treats these companies as a source of business, NOT direct competition.
- c. Direct Service Competitors:
- i. Tier 1 players such as Accenture provide comprehensive services to the industry with a “big” service model. They are limited in number. These companies often are engaged with the large hospital systems and are subject to the same “big” inflexibility of larger corporations, are costly, and do not address the core leakage issue leaving white spaces and large revenue leaking problems un-addressed.
 - ii. Tier 2 players are medium sized players owned by private equity that are built to sell and have no domain capacity other than what they bought and little capacity to strategically think quickly. There are a handful of these players. Private equity is attracted to this space, which validates to some extent the opportunity, but private equity firms need to deploy large sums of capital which often results in ineffective returns on cash invested. Some of these companies could become larger future acquisition targets for Certive.
 - iii. Tier 3 companies are smaller players that are part of the fragmented nature of this tier. They have customer access, and good principals, but are cash limited and have no long-term vision for how they fit into the market. That makes them perfect acquisition targets for Certive where it could acquire attractive clients and/or service niches, layer in its strategies, use the vast data it acquires to drive the development of better tools for long-term risk management and become a sought-after enterprise.

Critical Success Factors for Certive

There are several key indicators for the Company’s success in the Lost Charge and Denied Claims sector of the U.S. RCM market segment as follows:

Connectivity and Credentialing: The U.S. hospital market is comprised of hospitals that are run by a closely associated group of CEO's and CFO's who know each other as a result of migrations from hospital to hospital as industry challenges demanded changes to C level executive positions. Insofar as they are the only point of contact for vendors in the RCM space, it is critical to be connected through association and more importantly to be highly regarded and credentialed in the provision of audit and recovery services. The Company's acquisition of the assets of Titan and Omega brings with it over twelve years of service to this market and a highly credentialed and well-recognized management and staff who have performed seamlessly for their hospital customers.

Technology: CH intends to grow through acquisition of RCM companies providing services similar to that of Omega or to simply grow the current business organically. It is essential that the Company utilizes internally adaptable and compatible cloud workflow and analytical tools to address the many business opportunities in the RCM market. The acquisition of the Omega assets brought with it a suite of software tools utilized by Omega in the delivery of their business that are portable to Titan and other acquisition targets. These tools and others will enable scaling of the consolidated enterprise which is the key to growth and claims adjudication.

Domain Expertise: The Company acquired over 70 years of combined U.S. healthcare expertise. The principals of Omega have worked on both the provider and payer side of the industry and have an intricate knowledge of technical, regulatory and clinical landscapes necessary to navigate the target opportunities. With the establishment of the Advisory Council, the Company further enhanced its domain expertise by securing the input and direct contributions of seven highly credentialed individuals with a collective 300 years of expertise in U.S. healthcare (see Advisory Council roles below). This is perhaps the most important component in the Company's assessment of critical success factors.

Lines of Business

Charge Accuracy Audits

Revenue Integrity Analytics: Analytical software tools are utilized by Omega, combined with investigative expertise to identify risks and opportunities in the revenue cycle. Revenue integrity analytics services are offered on a real-time basis to analyze charging and billing issues that reduce or delay reimbursement. These services include claims analysis for coding integrity, audit and recovery of missing charges and analysis of revenue cycle for improved performance.

Revenue Recovery Services: This comprehensive clinical review of outpatient claims ensures that all documented items were billed, that all billed items were charged appropriately, and that all payments were in accordance with designated contracts

Missing Charge Software: OCExaminer software was developed based on nearly 20 years of experience in performing revenue recovery. Omega offers exclusive lost charge edits that are designed to quickly identify revenue enhancement opportunities

CDM Integrity Software: The charge master is the heart of the hospital's revenue cycle. Omega's ChargeMASTER application is designed to ensure that the hospital's charge master is complete and compliant. ChargeMASTER provides real-time validation, unlimited licensing, and iPhone™ simplicity, allowing hospital staff to quickly and easily maintain the clinical data management (CDM).

Contract Analysis Service: Hospitals are typically reimbursed in accordance with contract terms. Omega has developed proprietary technology that facilitates a quick analysis of claims information to ensure that payment is being made correctly.

Remote Coding: Increasingly, HIM directors are turning to outside resources to keep accounts moving. Omega has a large staff of certified coders to provide outsourced remote coding.

Technology and Scale

A brief description of the software products is set forth below:

i) ChargeMASTER: ChargeMASTER is a comprehensive resource for hospital chargemaster and management information system (MIS) staff. Since it is a web-based application, *ChargeMASTER* is available to analyze the CDM any time. The system can instantly pinpoint items that need to be updated for regulatory compliance and identify new or revised codes that will increase reimbursement yields.

ChargeMASTER contains 3 modules:

- Coding Alerts: invalid/incorrect Healthcare Common Procedure Coding (HCPC)/Current Procedural Terminology(CPT)/Revenue Codes, Fraud and Abuse Alerts
- Pricing Analysis: uniform pricing issues and charges that are below Outpatient Prospective Payment System (OPPS) payment rates
- CDM Modeling: Companion Code models, CPT department models

In addition, *ChargeMASTER* provides *information* to assist the user in identifying possible *solutions*.

A *ChargeMASTER* report completes the following functions and is used internally by Omega to provide the following revenue integrity services to its customers: Shows how/where to immediately bring the CDM into regulatory compliance, identifies coding errors that would cause claims to be rejected, identifies linked (companion) codes that are missing from the CDM, identifies charges that are below OPPS rates, and shows how to correct errors so they do not recur.

ii) OC Examiner Charge Capture Software: OCExaminer delivers unique charge capture software designed to help hospitals optimize its revenues. Omega's 20 years of experience in performing hands-on lost charge recovery engagements has resulted in the development of an unmatched revenue capture software. OCExaminer is designed to analyze claims to ensure that any potentially missing charges are identified prior to submitting the bill.

There are five core components of OCExaminer's (Charge Accuracy Audits) edits:

- Interventional Radiology
- Drug Administration
- Carve Outs
- Omega's Proprietary Edits
- User-defined Edits

OCExaminer typically identifies between an 8% and 15% potential error rate on previously scrubbed claims.

It also helps ensure compliance by automatically checking for:

- Medicare and Medicaid coding issues
- RAC alerts
- NCDs and LCDs

iii) One Point: **OnePoint** is a web based single point source for hospitals and MIS staff Certive's revenue Cycle Solutions since it is a web-based application.

OnePoint contains 6 modules;

- ChargeMASTER
- OCExaminer
- Patient Eligibility Determination
- Claims Management
- Remittance Advices
- Work Flow for both ChargeMaster and OCExaminer

Growth Strategy

CH's Lost Charge Recovery and OCExaminer claim scrubbing solutions, in management's view, provide better results vs. our competitors. As a small company with a strong offering and relatively limited resources, Certive will pursue three parallel strategies for growth. Business development with hospitals is almost exclusively built upon relationships with hospital CFO's. In the absence of acquiring the relationships it would be virtually impossible for any new entrant to this segment to even secure a first meeting with a hospital CFO.

The first strategy is an awareness and direct marketing campaign. Through the use of contemporary digital marketing tools, we will increase our presence in the market. The second strategy will be partnerships with companies having mutually complementary interest at the service or client relationship level. The third strategy will be to leverage another unique advantage possesses CH possesses which is volume capability without compromising quality. With this capacity we can therefore go to the large business process outsource firms and offer them the ability to sell solutions under a white-label agreement that they don't currently have or are not particularly competitive in. Occasional acquisitive opportunities to complement CH's growth strategy is to acquire customers

through relationships and via acquisition of select services or technologies that leverage our solutions to improve client satisfaction.

CH intends to invest in technology, that will improve value for clients, and improve margins. Charge Accuracy Audit and collections of claims are steps in a complicated process involving large quantities of claims and data. Skilled labor will always be part of the operational component of these services, but operational efficiency is a critical success factor to drive improved margins, scalability for growth, and the delivery of a differential value proposition for competitiveness. Analytical capabilities are also increasing in importance. The most immediate investment with the highest return will be an investment by CH in people with an exceptionally a high degree of connectivity with clients.

The Company's growth strategies are being refined as the Advisory Council and management address the strategic and tactical processes to grow. The most profitable way to grow is organically with competitive product offering possessing IP. To that end, development of differentiated solutions, relying upon Certive's core technologies will permit the development of new product offerings.

2017- 2018 STRATEGIC PLAN OVERVIEW

A summary of our near- term objectives are as follows;

- a) The CH has contracted with a C-level sales and marketing executive with 28 years' experience in our specific segment to assist in the identification of and closing of business where either he has direct contacts with decision makers or where he can take leads from other connectors within the Company's network.
- b) CH intends to expand its presence in the revenue cycle management segment by incrementally developing five additional and complementary solutions and bundle them into a single platform for efficiency and accuracy. New lines of business focused on the financial risks and outcome risks of health care not only for today's fee-for-service model, but will accelerate and enable key aspects of healthcare reform. These lines of business will be built using of a combination of current capabilities, development of sophisticated new analytical models on top of our current capabilities, and strategic acquisitions. These solutions will not only capture the leakage in the system but will provide defined process improvements in several niche areas to solve the root cause of the problem. The program will be led by one of Certive Health's Advisory Council members who has over 28 years' experience in healthcare and is founder and owner of a well-known healthcare analytics and actuarial services company and is focused on healthcare reform for State Medicaid programs. His firm holds the position as the second largest actuary of record to individual States in the U.S.
- c) CH has defined and will implement a best in class a digital web presence to attract investors, clients, and potential acquisition or partner candidates. This digital marketing program is designed to communicate more about the company and its core vision to attract people who bring accretive talent, ideas, or their companies for Certive to evaluate for potential acquisition.

d) Near Term Sales Strategies for Omega:

- Repurpose one of Omega's current employees to assist and coordinate all business development activities. This has been done and is presently exhibiting positive results.
- Realign with existing connectors to support both the Pittsburgh markets and Minnesota markets given the existence and willingness of the various connectors to work closely with the Chief Growth Officer.
- Utilize the existing contacts surrounding the sales executive referred to above to identify near term service offerings for which Omega can provide, including of course the core business of Lost Charge Recovery.
- New Sales and Marketing strategy will be led by the Chief Growth Officer.
- We have implemented a vastly expanded, comprehensive Managed Care Underpayment Recovery solution to existing clients. The rollout began with a pilot project at two existing clients to identify all underpayments from \$50 and above with expected high volumes of smaller balance recoveries re-submitted in batch mode. A successful pilot will result in applying the processes across all current and future clients.
- Commercial insurers, Medicare and Medicaid rate of claim denials have reached an all-time high of 14% of total claims. The extraordinarily high percentage of denials are often caused by physicians not documenting patient charts sufficiently to establish medical necessity. We are embarking on a pilot project with one of the industry's leading clinical coders who has trained hospital-based physicians across the country on the importance of clinical documentation to avoid denied claims and to more accurately capture the intensity and severity of the services performed. Not only will this eliminate a high volume of denials alleging a lack of medical necessity, it will also help our clients to recover additional funds on those denials plus increase their Case Mix Index which is used in the overall reimbursement computations assigned to all hospitals by Medicare and Medicaid. We also have access to partner with a firm that has the only software of its kind to identify the physicians who are the poorest performers at their hospital when it comes to documenting medical records. The software goes on to provide training by specialty and includes a self test at the end.

Other possible enhancements/new offerings under consideration include:

- Strategically offering a product to gain more market share in the Lost Charge Recovery space. Since the OCE tool consistently finds 10-12% more missing charges on Medicare and Medicaid outpatient claim than competing solutions, the product would focus on these government plans. We anticipate that strong performances on the government claims would allow us to capture the commercial Lost Charge Recovery business at approximately 50% of the hospitals that pilot with us.
- A number of solutions could be offered on a SaaS based platform for smaller hospitals that do not have a large enough volume of recovery potential to be a viable contingency fee client of ours. However, the lost charge, underpayment volume could be enough to entice these smaller hospitals to purchase a low-cost version of our current and future solutions on a monthly recurring license fee.

- The top two liabilities for hospitals are Payer Mix and Claim accuracy. Certive Health's solutions can be extended into identifying these risks for hospitals reducing potential liability and can be used can by Liability Insurance providers to evaluate and possible reduce premiums for hospitals.

Overall Performance for the nine months ended February 28, 2018

The following discussion of the Company's financial performance is based on the consolidated financial statements for the nine months ended February 28, 2018 and February 28, 2017. It should be noted that the results for the nine ended February 28, 2018 differ materially from the comparative period insofar as the current nine months does not include any operating results for the Titan Division as it was sold effective June 1, 2017.

As of February 28, 2018, the Company had a cash and cash equivalents balance of \$110,149 (May 31, 2017 - \$138,258), accounts receivable of \$445,074 (May 31, 2017 - \$501,322), prepayment of \$Nil (May 31, 2017 - \$16,597), and total current assets of \$555,223 (May 31, 2017 - \$656,177). The decrease in total current assets (\$100,954) was mainly in the area of accounts receivable. The decrease in accounts receivable was not material and is based on the level of activity in Omega.

There were no significant changes in non-current assets which were \$2,060,495 at February 28, 2018 (May 31, 2017 - \$2,100,855), insofar as the total assets were deemed sold at May 31, 2017. (See paragraph below).

For the year end (May 31, 2017) a new asset class was set up on the Balance Sheet. "Assets from Discontinues Operations". All the assets and liabilities of Titan as at May 31, 2017 have been removed from the statement of financial position of the Company. The Company has valued its investment in Titan as at May 31, 2017 at \$182,886, being the value of the shares to be returned and the cash to be acquired upon final settlement. There are currently no assets held for disposition at February 28, 2018.

Current liabilities at February 28, 2018 total \$4,770,284 (May 31, 2017 - \$3,096,409), the increase is due to several factors.

Accounts payable has increased by \$858,985 from the prior period to be \$2,229,658 as at February 28, 2018. Convertible debt increased by \$609,221 from the prior year to be \$2,037,470 as at February 28, 2018. The increase in the accounts payable and accrued liabilities is due to accrued interest charges, amounts due for payroll taxes, legal and accounting as well as trade obligations.

Accrued liabilities total \$1.2 m. A majority or \$1.1 m of these accruals are charges for internal contractors and members of the Advisory Council. Management is of the view that substantially all of the accrued liabilities charged by contractors and members of the Advisory council will be settled by the issuance of shares, thus positively impacting the working capital position (see adjusted working capital).

The balance of approximately \$840,000, is comprised of amounts owing to arms-length vendors and the IRS and accrued interest on outstanding short-term loans and convertible debt for \$235,000 of the total.

The convertible debt increased by \$609,221 from May 31, 2017. This net increase represents additional convertible debt secured by the company during the nine months ended February 28, 2018, adjusted for IFRS requirements to segregate the gross amount of the debt between equity and recorded balance sheet debt. Generally, debt obligations that include warrant coverage are first adjusted to reflect the present value of the debt and the difference between the present value of such debt and the face of the debt becomes the allocation between debt and equity on the balance sheet. Warrants are treated for the purpose of the allocation as a transaction cost and allocated between debt and equity on the same basis. Please see the table disclosure in Note 13 of the financial statements for further information.

Short term loans increased by \$205,669. The increase is the net result of the following:

- Increase of \$240,000 which was received as an advance from ASX Blockchain (see related party transaction section below)
- Certain short-term notes were reclassified to convertible debt
- Additional funds were received from new investors

The sum total of these changes resulted in the net increase to short term loans.

A derivative liability of \$235,014 has been recorded. This consists of the fair value of non-compensatory share purchase warrants and convertible notes that have an exercise price or a conversion price that differs from the functional currency of the Company. These warrants were valued using the Black Scholes option pricing model with a weighted average expected volatility of 163.99%, discount rate of 0.69%, expected life of 1.65 years, and a dividend rate of 0%.

Working capital, which is comprised of current assets less current liabilities, is (\$4,215,061) at February 28, 2018 as compared to (\$2,440,232) at May 31, 2017. The increasing working capital deficiency is caused by several factors. Firstly, the continuing cost of operating the Omega Division has caused the Company to seek additional third party financing, largely in the form of convertible debt. Management believes that all the additional convertible debt will in fact be converted. Secondly, the Company adjusted and accrued additional charges for internal service providers. In the context of the POA referred elsewhere these accruals will be settled by way of issuance of shares. See adjusted working capital schedule.

While management believes that near term (6 months) revenue opportunities exist that may mitigate or eliminate these cash flow deficiencies, the continued funding of the payroll burden is financially straining.

To date, the CH management group has not yet taken steps to reduce operating costs. CH management is however, hopeful that new sales and marketing initiatives being undertaken by its chief growth officer will positively impact operating cash requirements. At the date of this MD&A the Company is not assuming the responsibility for funding these working capital deficiencies in furtherance of the POA. The responsibility for funding CH now rests with the CH board.

During the nine months ended February 28, 2018, the Company reported a net loss of (\$2,350,977), ((\$0.03) basic and diluted income per share based on 79,315,738 weighted average number of common shares) compared to a net loss of (\$2,332,875), (\$0.03) basic and diluted income per share based on 71,657,760 weighted average number of common shares) for the nine months ended February 28, 2017.

RESULTS OF OPERATIONS - Nine Months Ended February 28, 2018: Certive Solutions Inc.

Results of operations are reported on a comparative basis with the nine months ended February 28, 2017. The Titan division was divested on June 1, 2017. Thus, the comparative financial statements are difficult to compare given the fact the current period excludes Titan and the prior period includes Titan. The following table shows the nine months ended February 28, 2018 compared to the nine months ended February 28, 2017 with Titan excluded.

Certive Solutions Inc.				
Condensed Interim Statements of Comprehensive Loss				
(Expressed in U.S. Dollars)				
	2018-02-28	2017-02-28	2/28/17 Titan	2/28/17 w/o Titan
REVENUE				
Billing support	\$ -	\$ 961,087	\$ 961,087	\$ -
Claim audit and collections	-	1,885,892	1,885,892	-
Consulting	163,651	202,790	-	202,790
Chargemaster revenue	948,856	1,039,782	-	1,039,782
Dashboard sales	126,098	60,377	-	60,377
Total revenue	1,238,605	4,149,928	2,846,979	1,302,949
OPERATING COSTS				
Commission	30,010	101,029	78,183	22,846
Contractors and consultants fees	317,595	394,717	39,920	354,797
Direct Payroll and employees benefits	716,879	2,389,104	1,337,771	1,051,333
Travel to client sites	4,199	28,310	27,176	1,134
License Fees	150	4,712	4,334	378
Total operating costs	1,068,833	2,917,872	1,487,384	1,430,488
Gross profit	169,772	1,232,056	1,359,595	- 127,539
EXPENSES				
Advisory board fees	60,000	112,500	-	112,500
Allowance for doubtful accounts	-	-	-	-
Amortization	64,957	78,593	2,403	76,190
Bank charges interest	302,587	219,672	32,785	186,887
Consulting fees	240,700	186,250	-	186,250
Corporate finance	72,300	132,150	-	132,150
Directors' fees	152,200	55,000	-	55,000
Foreign exchange (gain) loss	(184,889)	(22,786)	-	- 22,786
General and administrative	163,529	330,189	189,886	140,303
Investor relations	7,500	166,217	-	166,217
Management fees	429,000	410,000	-	410,000
Professional fees	305,561	275,775	19,990	255,785
Rent	185,166	279,736	92,684	187,052
Salaries and wages	581,038	692,204	365,121	327,083
Sales and marketing	10,510	49,535	-	49,535
Transfer agent and filing fees	29,696	23,209	-	23,209
Travel and promotion	134,587	144,303	26,844	117,459
Total expenses	2,554,442	3,132,547	729,713	2,402,834
	(2,384,670)	(1,900,491)	629,882	(2,530,373)
Share-based compensation expense		(432,384)		(432,384)
Foreign derivative expense	33,693			-
Recovery from settlement of debt			-	-
Loss from continuing operations	\$ (2,350,977)	\$ (2,332,875)	\$ 629,882	\$ (2,962,757)
Revenue from discontinued operations				
Expenses from discontinued operations				
Income from discontinued operations	0			
Loss and comprehensive loss for the year	\$ (2,350,977)	\$ (2,332,875)	\$ 629,882	\$ (2,962,757)

Revenue

The Company generated \$1,238,605 in gross revenue for the nine months ended February 28, 2018, compared with \$4,149,928 for the nine months ended February 28, 2017, a decrease of \$2,911,323, or 65.8%. In the first nine months of 2017, the Titan division contributed \$2,846,979 of revenue, which accounts for this decrease. A reasonable comparative analysis between the two reporting periods as noted above would be revenue from Omega division exclusive of Titan which would have been otherwise \$1,302,949. Therefore, the decrease in revenue between comparative periods accounting only for the Omega division would have been \$64,344. Effective June 1, 2017, the Company sold the Titan division and accordingly the decrease is in majority the result of the sale.

For the nine months ended February 28, 2018, the Company recorded gross revenues of \$1,238,605, of which Consulting Services accounted for \$163,651 with Chagemaster sales totaling \$948,856 and Dashboard sales totaling \$126,098.

For the nine months ended February 28, 2018, Omega recorded gross revenues of \$948,856 as compared to \$1,039,782 for the comparative nine months ended February 28, 2017 a decrease of \$90,926 or 9%. While fluctuations in gross revenue would traditionally be considered normal, CH has a continuing need to increase sales volumes generally. This will be accomplished in part by better connections with our customers and identifying needs and opportunities for which we have the capacity to deliver. CH will become much more aggressive in seeking ancillary revenue opportunities that are both viable and available, within our existing customer base.

Consulting revenues generated by KCA for the nine months ended February 28, 2018 were \$163,651 as compared to \$202,790 for the nine months ended February 28, 2017 a decrease of \$39,139 or 19% because of reduced consulting services previously provided to Maricopa County and a re-focus on targeting sales efforts to the dashboard product. See other sections of this MD&A for further information on the dashboard product.

Dashboard sales increased by \$65,721 to \$126,098 or 109% over the corresponding period. It should be noted that although the revenue being generated by KCA is still maturing, it clearly demonstrates the highly accretive nature of this division. The significance of dashboard sales is that as KCA matures to a licensing model from a consulting model and the platform secures national adoption by public health units, this division will generate significant accretive high margin revenue for the Company.

Operating Expenses

Commission expense decreased by \$71,019 to \$30,010 for the nine months ended February 28, 2018 from \$101,029 in the nine months ended February 28, 2017. In the first nine months of 2017, the Titan division contributed \$78,183 of commission, which accounts for the decrease. Both KCA and Omega have also started to use commissions as well and collectively this cost was \$30,010 in the current year ended February 28, 2018. The majority of which was due to hiring a commissioned sales agent for KCA.

Contractors and consulting fees decreased by \$77,122 to \$317,595 for the nine months ended February 28, 2018 from \$394,717 in the nine months ended February 28, 2017. The decrease in contractor and consulting fees is related to \$39,920 of Titan expense for the nine months of 2017 and a \$18,500 decrease in Omega's contractor costs.

For the nine months ended February 28, 2018, the Company reported direct payroll costs totaled \$716,879 or 58% of consolidated revenues for the period. This compares to \$2,389,104 or 57.5% of consolidated revenue for the comparative nine months.

Direct Payroll the nine months ended February 28, 2018 was \$716,879 as compared to the nine-month period ended February 28, 2017 which was \$2,389,104. The decrease in Direct Payroll and benefits is about \$1,672,225 and this decrease is due to a reclassification of Omega manager expenses of \$409,181 to salaries and wages under general overhead, in so far as during the nine months ended February 28, 2018 these managers spent the majority of their time on Certive related overhead while managing their divisions. Also, Titan had \$1,337,771 of Direct Payroll expense in nine-month period ended February 28, 2017 which contributed to the decrease.

Payroll costs associated with the operations of the Omega division exceed the current historical revenue pattern for the division. This has the result of a continuing need to fund cash flow deficiencies from external sources of capital. Only if the division can secure sales at a level that balances the cost of maintaining the facility and the staff associated with the delivery of the lost charge business, can the Company fund the growth opportunities that present themselves at this time.

Expenses (General Overhead)

General overhead expenses for the nine months ended February 28, 2018 totaled \$2,554,442 as compared to \$3,132,547 for the nine months ended February 28, 2017, a decrease of \$578,105 or 18.5% over the comparative nine months. Once an adjustment for Titan is made the comparable general overhead expenses is \$2,402,834 for the nine-month period ended February 28, 2017. The net difference in the two periods after factoring out Titan is \$151,608.

The following were the most significant changes for the nine-month period ended February 28, 2018:

Advisory Board Fees: The Company incurred \$60,000 in Advisory Board Fees during the nine months ended February 28, 2018 as compared to \$112,500 in costs for the nine months ended February 28, 2017. This represent a reduction of about \$52,500 or 47%. The reduction was primary due to lower payment to these members as a cost cutting measure and this represents management's efforts to reduce costs.

Interest and Bank Charges: Interest and bank charges for the nine months ended February 28, 2018 totaled \$302,587 as compared to \$219,672 for the nine months ended February 28, 2017. This increase is caused by increased accruals on increasing convertible debt balances.

Consulting Fees: Consulting fees of \$240,700 were paid in the nine months ending February 28, 2018, compared to \$186,250 for the nine months ended February 28, 2017. This increase of \$54,450 relates to the costs associated with Omega's Chief Growth Officer who joined in October 2017.

Corporate Finance Fees: The corporate finance fees decreased modestly from \$132,150 to \$72,300. Fees were paid on some of the Short-Term loans raised in the current quarter.

Director's Fees: Director's fees increased from \$55,000 for the nine months ended February 28, 2017 to \$152,200 for the nine months ended February 28, 2018. This represents an increase of \$77,200 or 176%. This increase is materially due to accruals made for expenditures incurred for services performed by directors of the Company.

General and Administrative Costs: General administrative expenses decreased from \$330,189 to \$163,529 for the nine months ended February 28, 2018, a decrease of \$166,660 over the comparative nine months. The decrease is related to the sale of the Titan division. Once Titan is factored out the comparative expense would have been \$140,303 for the nine months ended February 28, 2018 and this resulted in an increase of \$23,226.

Investor Relations Fees: Investor relations expenses of \$7,500 were incurred for the nine months ended February 28, 2018 compared to \$166,217 for nine months ended February 28, 2017. This decrease is consistent with the company reducing costs in this area. The Company is no longer conducting any investor relations activities at this time.

Management Fees: Management fees of \$429,000 were paid to senior management including divisional managers and the Company's interim COO, and other C level executives for nine months ended February 28, 2018, compared to \$410,000 for the same period in 2017, an increase of \$19,000.

Professional Fees: Professional fees paid for the nine months ended February 28, 2018 were \$305,561 as compared to \$275,775 for the comparative prior nine months, an increase of \$29,786 for the nine months. This increase stemmed from several areas. Both Legal and Audit expenses were higher in the current period.

Rent: Rent and occupancy costs for the nine months ended February 28, 2018 totaled \$185,166 as compared to \$279,736 for 2017. Of the \$94,570 decrease, \$92,684 is attributed to the Titan division.

Salaries and Wages: The reported Salaries and Wages decreased to \$581,038 from \$692,204. This decrease in Salaries and Wages of \$111,166 is mainly attributable to Titan be removed from operations. Once Titan is removed the expense for the prior period, the comparative expense would have been \$327,083. The increase difference of \$253,955 is attributed to the fact Senior Omega Management expenses were reclassified to this expense category in the current period from Direct Payroll.

Sales and Marketing: The Company incurred \$10,510 of sales & marketing costs during the nine months ended February 28, 2018 as compared to \$49,535 costs for the nine months ended February 28, 2017. During the 2017 period a sales and marketing consultant was on staff for a short period. This proved to be unsuccessful and was discontinued. Trade show expenses for KCA contributed to most of the cost in 2018.

Travel and Promotion: Travel and promotion costs for the nine months ended February 28, 2018 were \$134,587 compared to \$144,303 for the comparative nine months ended February 28, 2017. The decrease in travel costs is immaterial and related to period travel costs which vary quarter to quarter.

The comprehensive loss for the nine months ended February 28, 2018 was \$2,350,977 as compared to \$2,332,875 for the nine months ended February 28, 2017.

The fully diluted loss for the nine-month period per share outstanding as at February 28, 2018 was \$0.03 per share calculated based on 79,315,738 consolidated weighted average common shares outstanding.

RESULTS OF OPERATIONS – Three Months Ended February 28, 2018: Certive Solutions Inc.

Results of operations are reported on a comparative basis with the three months ended February 28, 2017.

The Company generated \$353,653 in gross revenue for the three months ended February 28, 2018, compared with \$1,259,820 for the three months ended February 28, 2017, a decrease of \$906,167. Once Titan is factored out the 2017 revenue was \$379,240 or a decrease of \$25,587 and virtually all of this decrease was in the Omega Operations.

Expenses

Expenses were \$551,906 for the three months ended February 28, 2018 compared to \$1,033,051 for the period ended February 28, 2017. The following are the most significant

Bank charges and interest: a decrease of \$18,309

General and Administrative: a decrease of \$33,203

Investor relations: a decrease of \$96,217

Sales and Marketing: an increase of \$15,133

Salaries and Wages: a decrease of \$85,259

Details behind the decrease in each category are described above. As the Company, moves to positive free cash there will be a concurrent effort to consolidate operating overheads.

FINANCIAL POSITION

As at February 28, 2018, the Company had a working capital deficiency of \$4,215,061. However, there are current liabilities that are scheduled for conversion to equity.

The adjusted working capital should be as follows:

Certive Solutions, Inc Adjusted Working Capital Calculation

Total Current Assets:				\$ 555,223
			<u>Accounts Payable & Accrued Liabilities</u>	<u>Total Adjusted Current Liabilities</u>
	<u>Convertible Debt</u>	<u>Short Term Loans</u>		
Current Liabilities:	2,037,470	503,156	2,229,658	4,770,284
Amounts to be converted:				-
Convertible Unsecured	(2,037,470)			(2,037,470)
Amounts paid subsequent to year end Convertible amounts owing to Directors & Advisory Board Members			(1,100,000)	(1,100,000)
Other Convertible Loans		(503,000)		(503,000)
Total Adjusted Current Liabilities	-	156	1,129,658	1,129,814
Net Working Capital				<u><u>\$ (574,591)</u></u>

SELECTED ANNUAL INFORMATION

The following financial data, which has been prepared in accordance with International Financial Reporting Standards (IFRS), is derived from the Company's financial statements. These sums are being reported in U.S. dollars and did not change as a result of the adoption of policies concerning Financial Instruments.

	May 31, 2017	Year ended May 31, 2016	May 31, 2015
Total Revenue	\$ 1,716,666	\$5,634,770	\$3,862,837
Interest income	\$--	\$--	\$--
Expenses	\$ 5,661,388	\$11,370,457	\$6,177,515
Net loss	(\$3,741,115)	(\$5,735,687)	(\$2,314,678)
Total assets	\$2,939,918	\$5,879,498	\$4,496,007

Total long-term liabilities	\$	\$--	\$--
Net loss per share (basic and diluted)	(\$0.05)	(\$0.11)	(\$0.06)

As noted elsewhere in this MD&A the results of operations for the Titan Division have been reported in the Statements of Comprehensive Loss in aggregate as Discontinued Operations. The impact on revenue in the above schedule where \$3,787,947 of Titan revenue for the year ended May 31, 2017 has been reflected in Discontinued Operations. Please see section “Summary of Corporate Status as at May 31, 2017”

SELECTED QUARTERLY INFORMATION

The following table summarized the results of operations for the four most recent quarters.

	Three months ended			
	February 28, 2018	November 30, 2017	August 31, 2017	May 31, 2017
Total Revenue	\$353,653	\$447,392	\$437,561	\$1,354,685
Interest income	\$ --	\$ --	\$ --	\$ --
Expenses	\$900,288	\$1,177,161	\$1,512,133	\$2,174,298
Net loss	(\$546,635)	(\$729,769)	(\$1,074,572)	(\$819,613)
Net loss per share and diluted loss per share	(\$0.01)	(\$0.01)	(\$0.01)	(\$0.01)

	Three months ended			
	February 28, 2017	November 30, 2016	August 31, 2016	May 31, 2016
Total Revenue	\$1,259,820	\$ 1,373,808	\$ 1,516,300	\$ 1,139,211
Interest income	\$ --	\$ --	\$ --	\$ --
Expenses	\$2,001,646	\$2,534,823	\$1,946,334	\$3,871,038

Net loss	(\$741,826)	(\$1,161,015)	(\$430,034)	(\$2,731,827)
Net loss per share and diluted loss per share	(\$0.01)	(\$0.02)	(\$0.01)	(\$0.04)

Summary of Quarterly Results

For the quarter ended February 28, 2018, the Company recorded revenues only for the Omega and KCA divisions. Compared to February 28, 2017 without Titan, revenue decreased by a modest 5% from the corresponding period in the prior year.

LIQUIDITY

- a) As at the date of this MD&A, the Company does not have sufficient working capital to cover its operating overhead either corporately or divisionally. Sources of capital are being identified to address working capital needs. Both equity and debt financings are being contemplated as potential sources of working capital. The Company is also contemplating a re-organization plan that may lead to additional sources of financing. In order for the Omega division to fully support its operating costs, it must generate a minimum of \$200,000 per month in revenue. Presently, the Omega division generates approximately \$90,000 in monthly revenues. With many new revenue categories being identified by management, the near term working capital problem are correctable. Fluctuations in liquidity will continue as long as the Omega Division operates at a loss. Reduction in staffing levels and /or modified work schedules are internal means by which the Company will control these variances.
- b) The Company does not currently have any liquidity risks associated with maturing financial instruments, other than certain notes that became due in June of 2017, totaling CDN\$290,000. Proposed settlements have been made to the creditors and as of the date of this MD&A the Company has had two responses from a total 6 settlement offers.
- c) The Company's working capital deficiency will be substantially reduced after the conversions discussed in the MD&A are effected. The current working capital deficiency is \$4,215,061 (adjusted \$574,591). There are no balance sheet conditions or income or cash flow items that may materially affect the Company's liquidity other than the ability to generate revenue from existing customer contracts. Readers are directed to Note 1 in the Financial Statements for additional information.
- d) The Company has two subsidiaries, one of which has two operating units at the date of this MD&A.
- e) There are currently no defaults or arrears by the Company on dividend payments, lease payments, interest or principal payment on debt, debt covenants; redemption or retraction or sinking fund payments, other than certain notes represented as convertible debt in the aggregate amount of CDN\$290,000.

- f) The Company has accrued but not paid interest on all of its convertible debt. The terms of agreement with the companies note holders are that interest payments are convertible at the noteholders option into shares at defined prices at the term of the note. Therefore, the Company does anticipate any cash call for periodic interest payments prior to conversion.

CAPITAL RESOURCES

The Company has no planned capital expenditures at the date of this MD&A the allocation of capital during the following twelve months will be directed towards sales and marketing initiatives that will monetize the infrastructure presently in place and support the operating overheads of the public company.

OFF BALANCE SHEET ARRANGEMENTS

As at February 28, 2018 the Company had no off-balance sheet arrangements.

PROPOSED TRANSACTIONS

The Company does not have any other proposed transactions to discuss at this time.

TRANSACTIONS WITH RELATED PARTIES

- a) As of February 28, 2018, the Company had advanced \$504,885 to Canadian Data Preserve, Inc., a company with common directors. The common directors are Brian Cameron, Van Potter, and Mike Bartlett. The advances are secured with a promissory note bearing interest at 8% per annum. The advance has not been repaid at the date of this MD&A.

Canadian Data Preserve is currently undergoing an RTO transaction. An arm-length party has made an offer purchase the balance owed to the Company. As of the date of this MD&A the board has approved the acceptance of \$240,000 cash and 160,000 post consolidated shares of the resulting issuer from the Canadian Data Preserve RTO transaction. On January 29, 2018 the Company received \$240,000 which was recorded as an advance pending receipt of the shares. See subsequent events.

- b) During the nine months ending February 28, 2018, the Company paid or accrued management, consulting, and director's fees and salaries to key management persons totaling.

Directors Fee's

Mike Bartlett	\$ 117,200
Jeff Wareham	\$ 10,000
Ed Holder	\$ 25,000
Total	<u>\$152,200</u>

Advisory Board Fees

Jack Chapman	\$ 20,000
Tom Marreel	\$ 40,000
Total	<u>\$ 60,000</u>

Management Fees

Brian Cameron	\$ 214,500
Van Potter	\$ 214,500
Other Operational Managers	\$ <u>267,675</u>
Total	<u>\$ 696,675</u>

c) As of February 28, 2018, the Company loans receivable of \$504,885 from related parties as follows, which amount was written off by the Company in previous reporting periods.

i. Due from Canadian Data Preserve Inc. \$504,885

On January 22, 2018 the Company agreed to accept \$240,000 and 160,000 post consolidated common shares of Canadian Data Preserve Inc. in full satisfaction of this amount due.

d) As of February 28, 2018, the Company had Loans and Convertible Loans due to related parties as follows:

i. Loan due to Van Potter \$15,000
ii. Loans payable of \$129,181 are related party obligations to Omega and KCA. These loans are reflected on the balance sheet as part of the total \$503,156 shown on the balance sheet as short-term notes.

OUTSTANDING SHARE DATA

Authorized: unlimited common shares without par value
unlimited preferred shares without par value

Issued and Outstanding:

	Number of Shares	Amount
Balance at May 31, 2016	67,085,477	\$ 18,094,420
Private placement	2,101,523	\$ 630,456
Fair Value of warrants issued		\$ (148,345)
Stock Option exercise	3,294,924	\$ 622,848
Fair value of stock options exercised		\$ 526,467
Conversion of Debt	5,779,473	\$ 1,115,139
Shares issued for debt settlement	450,000	\$ 33,786
Shares issued for acquisition of KCA	900,000	\$ 67,572
Balance at May 31, 2017	79,611,397	\$ 20,942,344
Shares returned to treasury on		

Discontinuation of Titan	(2,240,667)	\$ (82,886)
Transaction costs on convertible debt	1,666,700	\$ 55,319
Balance at February 28, 2018	79,037,430	\$ 21,030,282

Stock Options:

The following stock options are currently outstanding:

Total outstanding Options May 31, 2016	12,297,417
Granted options	2,100,000
Exercised options	<u>(3,294,924)</u>
Total outstanding options May 31, 2017	<u>11,102,493⁽¹⁾</u>

⁽¹⁾ And February 28, 2018 and April 30, 2018.

Warrants:

The following warrants are outstanding:

As at February 28, 2018, the Company had the following share purchase warrants outstanding:

Outstanding	Exercise Price	Remaining Life (Years)	Expiry Date
2,101,523	\$0.35	0.54	September 12, 2018
1,600,000	CDN\$0.15	0.73	November 21, 2018
2,635,015	CDN\$0.50	0.75	November 30, 2018
254,722	CDN\$0.60	0.75	November 30, 2018
2,500,000	CDN\$0.15	0.90	January 23, 2019
3,333,400	CDN\$0.06	1.22	May 20, 2019
3,333,334	CDN\$0.06	1.29	June 15, 2019
875,000	\$0.15	2.00	February 28, 2020
4,250,000	\$0.06	2.00	February 28, 2020
9375,000	CAD\$0.04	2.00	February 28, 2020
2,000,000	\$0.05	2.00	February 28, 2020
32,257,994	\$0.11	1.49	

Total warrants outstanding at February 28, 2018 is 32,257,994

CONTINGENCIES

During the year ended May 31, 2017, the Company received correspondence from the Internal Revenue Services (“IRS”) with assessed penalties totaling \$94,217 regarding failure to report ownership of foreign assets. Management believes that all the correct forms were filed with the IRS on time, and has discussed these matters with the IRS. Management is of the opinion that this will be resolved, and that no penalties will be owing. As a result, no liability has been recorded on the statement of financial position as at November 30, 2017 or May 31, 2017

SUBSEQUENT EVENT

On January 29, 2018, the Company received \$240,000, which was recorded as an advance pending receipt of the share in partial satisfaction of an amount owing to the Company by Canadian Data Preserve, Inc. The balance of the receivable is being settled by way of the issuance of 160,000 common shares of the resulting issuer. When the Company received the shares, the full amount of the receivable will be deemed collected. The full amount of this receivable was previously written off due to management not being certain of the collectability of this amount (See Note 17 of the financial statements).

CONTROLS AND PROCEDURES

The Chief Financial Officer is responsible for establishing and maintaining effective disclosure controls and procedures for the Company as defined in National Instrument 52-109 *Certification of Disclosure in Annual and Interim Filings*. Management has concluded that as of October 28, 2011, discussion of disclosure controls and procedures is preemptive; however, once operations begin, such controls will be effective enough to provide reasonable assurance that material information relating to the Company would be known, particularly during the period in which reports are being prepared.

Disclosure controls and procedures

The Chief Financial Officer is responsible for establishing and maintaining effective disclosure controls and procedures for the Company as defined in National Instrument 52-109 *Certification of Disclosure in Annual and Interim Filings*. Management has concluded that as of October 28, 2011, discussion of disclosure controls and procedures is preemptive; however, once operations begin, such controls will be effective enough to provide reasonable assurance that material information relating to the Company would be known, particularly during the period in which reports are being prepared.

Internal control over financial reporting

The Chief Financial Officer is responsible for establishing and maintaining effective internal control over financial reporting as defined in National Instrument 52-109. Because of its inherent limitations, internal control over financial reporting may have material weaknesses and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management has concluded that internal control over financial reporting will be effective. The design and operation of internal control over financial reporting will provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with applicable generally accepted accounting principles.

Internal control over financial reporting will include those policies and procedures that establish the following: maintenance of records in reasonable detail, that accurately and fairly reflect the transactions and dispositions of assets; reasonable assurance that transactions are recorded as

necessary to permit preparation of financial statements in accordance with applicable generally accepted accounting principles; receipts and expenditures are only being made in accordance with authorizations of management and the Board of Directors; and reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets.

Management will design internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with Canadian GAAP.

Segregation of duties

Currently duties have not been segregated due to the small number of individuals involved in this start-up. This lack of segregation of duties has not resulted in any material misstatement to the financial statements.

As the Company incurs future growth, management plans to expand the number of individuals involved in the accounting and finance functions. At the present time, the Chief Executive Officer and Chief Financial Officer oversee all material transactions and related accounting records. In addition, the Audit Committee of the Company review on a quarterly basis the interim financial statements and key risks and will query management about significant transactions.

Complex and non-routine transactions

The Company may be required to record complex and non-routine transactions. These sometimes will be extremely technical in nature and require an in-depth understanding of Canadian GAAP. Finance staff will consult with their third-party expert advisors as needed in connection with the recording and reporting of complex and non-routine transactions. In addition, an annual audit will be completed and presented to the Audit Committee for its review and approval.

These consolidated financial statements, including comparatives have been prepared in accordance with International Accounting Standards (“IAS”) 1, “Presentation of Consolidated financial statements” using accounting policies consistent with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and interpretations issued by the International Financial Reporting Interpretations Committee (“IFRIC”).

The consolidated financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value as explained in the accounting policies set out in Note 3. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information. The comparative figures presented in these consolidated financial statements are in accordance with IFRS.

These consolidated financial statements were authorized by the audit committee and board of directors of the Company on April 30, 2018.

Comparative periods

Prior period comparative figures have been amended to conform to the current period's presentation. Previously, the Company's due from and due to related parties were reported separately on the statement financial position. They are now reported as a net figure under due from related party.

Use of estimates and judgments

The preparation of the consolidated financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statement. Actual results could differ from these estimates.

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the end of the reporting year, that could result in a material adjustment to the carrying amounts of assets and liabilities in the event that actual results differ from assumptions made, relate to, but are not limited to, the following:

i) Depreciation

The Company's management exercises its judgment in estimating the useful lives of the depreciable assets. The estimated useful lives reflect the management's estimate of the periods the Company intends to derive future economic benefits from the use of these assets. The Company depreciates its capital assets in accordance with the accounting policies stated in Note 3.

ii) Recovery of deferred tax assets

Judgment is required in determining whether deferred tax assets are recognized on the statement of financial position. Deferred tax assets, including those arising from unutilized tax losses require management to assess the likelihood that the Group will generate taxable earnings in future periods, in order to utilize recognized deferred tax assets. Estimates of future taxable income are based on forecast cash flows from operations and the application of existing tax laws in each jurisdiction. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be impacted.

Additionally, future changes in tax laws in the jurisdictions in which the Company operates could limit the ability of the Company to obtain tax deductions in future periods.

iii) Contingencies

By their nature, contingencies will only be resolved when one or more future events occur or fail to occur. The assessment of contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events.

Determination of functional currency

The functional currency is the currency of the primary economic environment in which the entity operates. Management has determined that the functional currency for the Company is the U.S. dollar. The functional currency determination was conducted through an analysis of the consideration factors identified in IAS 21, *The Effects of Changes in Foreign Exchange Rates*.

SIGNIFICANT ACCOUNTING POLICIES

Basis of consolidation

These consolidated financial statements include the accounts of the Company and its subsidiaries. Intra-company balances and transactions, and any unrealized income and expenses arising from intra-company transactions, are eliminated in preparing the consolidated financial statements.

Name of Subsidiary	Place of Incorporation	Proportion of Ownership Interest	Principal Activity
Advantive Information Management Inc.	Vancouver, BC	100%	Information Technology
Certive Heath Inc.	Scottsdale, Arizona	100%	Information Technology

Foreign exchange

Transactions in currencies other than the U.S. dollar are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, the monetary assets and liabilities of the Company that are denominated in foreign currencies are translated at the rate of exchange at the statement of financial position date while non-monetary assets and liabilities are translated at historical rates. Revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains and losses arising on translation are recognized through profit or loss.

Cash

Cash includes cash on hand, deposits held at call with financial institutions and other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amount of cash and subject to an insignificant risk of change value.

License

The initial cost of an asset comprises its purchase price or construction cost, any costs directly attributable to bringing the asset into operation, the initial estimate of the rehabilitation obligation, and for qualifying assets, borrowing costs. The purchase price or construction cost is the aggregate amount paid and the fair value of any other consideration given to acquire the asset. At the end of each reporting period, the License is reviewed to determine whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment, if any. See Note 7 for details.

Financial instruments

Financial assets

The Company classifies its financial assets into one of the following categories, depending on the purpose for which the asset was acquired. The Company's accounting policy for each category is as follows:

Fair value through profit or loss - This category comprises derivatives, or assets acquired or incurred principally for the purpose of selling or repurchasing it in the near term. They are carried in the statement of financial position at fair value with changes in fair value recognized through profit or loss.

Loans and receivables - These assets are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are carried at cost less any provision for impairment. Individually significant receivables are considered for impairment when they are past due or when other objective evidence is received that a specific counterparty will default.

Held-to-maturity investments - These assets are non-derivative financial assets with fixed or determinable payments and fixed maturities that the Company's management has the positive intention and ability to hold to maturity. These assets are measured at amortized cost using the effective interest method. If there is objective evidence that the investment is impaired, determined by reference to external credit ratings and other relevant indicators, the financial asset is measured at the present value of estimated future cash flows. Any changes to the carrying amount of the investment, including impairment losses, are recognized through profit or loss.

Available-for-sale - Non-derivative financial assets not included in the above categories are classified as available-for-sale. They are carried at fair value with changes in fair value recognized directly in equity. Where a decline in the fair value of an available-for-sale financial asset constitutes objective evidence of impairment, the amount of the loss is removed from equity and recognized through profit or loss.

The Company has not classified any financial assets as held-to-maturity or available for sale.

All financial assets except for those at fair value through profit or loss are subject to review for

impairment at least at each reporting date. Financial assets are impaired when there is any objective evidence that a financial asset or a group of financial assets is impaired. Different criteria to determine impairment are applied for each category of financial assets, which are described above.

The Company has classified its cash as fair value through profit or loss. The Company's receivables and due from related parties are classified as loans and receivables.

Financial liabilities

The Company classifies its financial liabilities into one of two categories, depending on the purpose for which the asset was acquired. The Company's accounting policy for each category is as follows:

Fair value through profit or loss: This category comprises derivatives, or liabilities acquired or incurred principally for the purpose of selling or repurchasing it in the near term. They are carried in the statement of financial position at fair value with changes in fair value recognized through profit or loss.

Other financial liabilities: This category includes promissory notes, amounts due to related parties and accounts payables and accrued liabilities, all of which are recognized at amortized cost. The Company's accounts payables and other liabilities, due to related parties, short term loans and convertible debt are classified as other financial liabilities.

Impairment

At the end of each reporting period, the Company's assets are reviewed to determine whether there is any indication that those assets may be impaired. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment, if any. The recoverable amount is the higher of fair value less costs to sell and value in use. Fair value is determined as the amount that would be obtained from the sale of the asset in an arm's length transaction between knowledgeable and willing parties.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount and the impairment loss is recognized in the profit or loss for the period. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash generating unit to which the asset belongs.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but to an amount that does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.

Loss per share

The Company presents basic loss per share for its common shares, calculated by dividing the loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted loss per share does not adjust the loss attributable to common shareholders or the weighted average number of common shares outstanding when the effect is anti-dilutive.

Income taxes

Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at period end, adjusted for amendments to tax payable with regards to previous years.

Deferred tax is recorded based on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes; the initial recognition of assets or liabilities that affect neither accounting or taxable loss; and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the statement of financial position date.

A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized.

Additional income taxes that arise from the distribution of dividends are recognized at the same time as the liability to pay the related dividend. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.

Related party transactions

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

Future accounting pronouncements

A number of new standards, amendments to standards and interpretations are not yet effective as at the date of issuing these statements, and have not been applied in preparing these financial statements. The Company has not early adopted any of these standards and is currently evaluating

the impact, if any, that these standards might have on its consolidated financial statements.

IFRS 9 - Financial Instruments, addresses classification, measurement and recognition of financial assets and financial liabilities. This new standard is a partial replacement of IAS 39, Financial Instruments: Recognition and Measurement. IFRS 9 introduces new requirements for the classification and measurement of financial assets, additional changes relating to financial liabilities, a new general hedge accounting standard which will align hedge accounting more closely with risk management. The new standard also requires a single impairment method to be used, replacing multiple impairment methods in IAS 39. IFRS 9 is effective for annual years beginning on or after January 1, 2018, with early adoption permitted.

IFRS 15 - Revenue from Contracts and Customers (“IFRS 15”) will replace IAS 18, Revenue, IAS 11, Construction Contracts, and related interpretations on revenue. IFRS 15 sets out the requirements for recognizing revenue that apply to all contracts with customers, except for contracts that are within the scope of the Standards on leases, insurance contracts and financial instruments. IFRS 15 uses a control based approach to recognize revenue which is a change from the risk and reward approach under the current standard. Companies can elect to use either a full or modified retrospective approach when adopting this standard and it is effective for annual years beginning on or after January 1, 2018, with early adoption permitted.

Interest-bearing loans and other borrowings

Interest-bearing loans and other borrowings are recognized initially at fair value less related transaction costs. Subsequent to initial recognition, interest-bearing borrowings are stated at amortized cost with any difference between cost and redemption value being recognized in the income statement over the period of borrowings on an effective interest basis.

Provisions

Provisions are recorded when a present legal or constructive obligation exists as a result of past events where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate of the amount of the obligation can be made.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation estimated at the end of each reporting period, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows. When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset if it is virtually certain that reimbursement will be received and the amount receivable can be measured reliably.

Share capital

Common shares are classified as equity. Transaction costs directly attributable to the issue of common shares and share purchase options are recognized as a deduction from equity, net of any

tax effects.

Revenue recognition

Contract revenue is recognized when goods are shipped and the customer takes ownership and assumes risk of loss, collection of the relevant receivable is probable, persuasive evidence of an arrangement exists and the sales price is fixed or determinable.

RISK FACTORS

Strategic and operational risks

Strategic and operational risks are risks that arise if the Company fails to develop sufficiently develop its strategic plans. These strategic opportunities or threats arise from a range of factors which might include changing economic and political circumstances and regulatory approvals and competitor actions. The risk is mitigated by consideration of other potential development opportunities and challenges which management may undertake.

Credit risk

Credit risk is the risk that one party to a financial instrument will cause a loss for the other party by failing to discharge an obligation. The Company is subject to normal industry credit risks. The Company's other receivable balance may consist of amounts outstanding on Harmonized Sales Tax Credits from Canada Revenue Agency. Therefore, the Company believes that there is minimal exposure to credit risk.

Liquidity risk

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at February 28, 2018, the Company had a cash and cash equivalent balance of \$555,223 and current liabilities of \$4,770,284 of which \$3,640,470 will be settled for stock.

Interest risk

Interest risk is the risk that the fair value or future cash flows will fluctuate as a result of changes in market risk. The Company's sensitivity to interest rates is currently immaterial.

Currency risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company holds no financial instruments that are denominated in a currency other than U.S. dollar. Cash and accrued liabilities are denominated in Canadian currency. Therefore, the Company's exposure to currency risk is minimal.

RISKS AND UNCERTAINTIES

Risk Factors

In evaluating an investment in the Company's shares, in addition to the other information contained or incorporated by reference herein, investors should consider the following risk factors. These risk factors are not a definitive list of all risk factors associated with the Company and its business.

General and Industry Risks

The Company's business objectives in the next 12 months are to establish, by the end of 2014, (i) an expanded profitable operating business that can be sustained on an ongoing basis, (ii) a strong market position that will permit the company to rapidly and profitably expand the market for its products, and (iii) significant competitive advantages that will permit the company to sustain its market shares and profit margins.

Securities and Dilution

The purpose of the concurrent financing is to raise funds to carry out the Company's business objectives with the ultimate objective of establishing a human resources company providing unique Web-based solutions to the small and medium-sized business enterprises. The only source of future funds presently available to the Company is through the sale of equity capital or the assumption of debt. There is no assurance that such sources of financing will be available on acceptable terms, if at all. If the Company seeks additional equity financing, the issuance of additional shares will dilute the interests of their current shareholders. Failure to obtain such additional financings could result in delay or indefinite postponement of the Company's strategic goals.

Competition

The computer software backup/recovery industry is intensely competitive in all of its phases, and the Company will compete with many companies possessing greater financial resources and technical facilities than the Company.

Conflicts of Interest

Certain of the Company's proposed directors and senior officers are directors or hold positions in other public companies. If any disputes arise between these organizations and the Company, or if certain of these organizations undertake transactions with the Company's competitors, there exists the possibility for such persons to be in a position of conflict. Any decision or recommendation made by these persons involving the Company will be made in accordance with their duties and obligations to deal fairly and in good faith with the Company and such other organizations. In addition, as applicable, such directors and officers will abstain from voting on any matter in which they have a conflict of interest.

No History of Earnings or Dividends

As a newly formed company, the Company has no history of earnings, and there is no assurance that the Company will generate earnings, operate profitably or provide a return on investment in the future. The Company has no plans to pay dividends for the foreseeable future.

Potential Profitability Depends Upon Factors Beyond the Control of the Company

The potential profitability of the Company is dependent upon many factors beyond the Company's control. Profitability also depends on the costs of operations, including costs of labor, equipment, electricity, regulatory compliance or other production inputs. Such costs will fluctuate in ways the Company cannot predict and are beyond the Company's control, and such fluctuations will impact on profitability and may eliminate profitability altogether. Additionally, events that cause worldwide economic uncertainty may make raising of funds for development difficult. These changes and events may materially affect the financial performance of the Company.

Dependency on a Small Number of Management Personnel

The Company is dependent on a relatively small number of key personnel, the loss of any of whom could have an adverse effect on the Company and its business operations.

Failure to perform contracts

Contracts for the Company's services may include penalties and/or incentives related to performance, which could materially affect operating results. Management provides for any anticipated penalties against contract value.

Project performance

Any inability of the Company to execute customer projects in accordance with requirements, including adherence to timetables, could have a material adverse effect on the Company's business, operations and prospects.

Intangible asset impairment

The Company has recognized the value of its contracts and customer list as an intangible asset. The Company assesses these assets periodically to evaluate if value recognized as an asset has become impaired. If the Company were to determine that the applicable expected future cash flows do not support the intangible asset book values, impairment would need to be recognized that could have an adverse impact on the financial results of the Company.

Future capital requirements

The Company's future capital requirements will depend on many factors, including inorganic growth initiatives, securing new contracts, the rate of expansion and the status of competitive products. Depending on these factors, the Company may require additional financing which may or may not be available on acceptable terms. If additional funds are raised by issuing equity securities, dilution to the existing shareholders may result. If adequate funds are not available, the Company may not be able to achieve its growth objectives and operational targets, which could have a material adverse effect on the Company's business.

Officers and Directors

Van Potter

Director

Brian Cameron

CFO & Director

Michael Bartlett
Jeffrey Wareham
Scott Thomas

Executive Chairman of the Board and CEO
Director
Director

Contact Address

Certive Solutions Inc.
1140-1185 West Georgia Street
Vancouver, B.C.
V6E 4E6